美国约翰霍普金斯大学Janis M. Taube研究小组发现天文学分析平台AstroPath可用于揭示PD-1阻断的疗效。相关论文于2021年6月11日发表于国际学术期刊《科学》。
研究人员介绍了一个综合平台，可用于具有高保真单细胞分辨率的肿瘤组织切片中的多个参数的多谱段成像和映射。图像分析和数据处理组件来自天文学领域。使用这个“AstroPath”全载玻片平台和六个标记，研究人员确定了预处理黑色素瘤标本的关键特征，这些特征预测对基于抗程序性细胞死亡-1（PD-1）的治疗的反应，包括CD163+PD-L1-骨髓细胞和CD8+FoxP3+PD-1low/midT细胞。这些特征被整合用来对PD-1阻断后的长期生存进行分层。该特征在来自不同机构的黑色素瘤患者独立队列中得到验证。
据了解，用于免疫治疗的下一代基于组织的生物标志物可能包括同时分析多种细胞类型及其空间相互作用，以及免疫调节分子的不同表达模式。
附：英文原文
Title: Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade
Author: Sneha Berry, Nicolas A. Giraldo, Benjamin F. Green, Tricia R. Cottrell, Julie E. Stein, Elizabeth L. Engle, Haiying Xu, Aleksandra Ogurtsova, Charles Roberts, Daphne Wang, Peter Nguyen, Qingfeng Zhu, Sigfredo Soto-Diaz, Jose Loyola, Inbal B. Sander, Pok Fai Wong, Shlomit Jessel, Joshua Doyle, Danielle Signer, Richard Wilton, Jeffrey S. Roskes, Margaret Eminizer, Seyoun Park, Joel C. Sunshine, Elizabeth M. Jaffee, Alexander Baras, Angelo M. De Marzo, Suzanne L. Topalian, Harriet Kluger, Leslie Cope, Evan J. Lipson, Ludmila Danilova, Robert A. Anders, David L. Rimm, Drew M. Pardoll, Alexander S. Szalay, Janis M. Taube
Issue&Volume: 2021/06/11
Abstract: Next-generation tissue-based biomarkers for immunotherapy will likely include the simultaneous analysis of multiple cell types and their spatial interactions, as well as distinct expression patterns of immunoregulatory molecules. Here, we introduce a comprehensive platform for multispectral imaging and mapping of multiple parameters in tumor tissue sections with high-fidelity single-cell resolution. Image analysis and data handling components were drawn from the field of astronomy. Using this “AstroPath” whole-slide platform and only six markers, we identified key features in pretreatment melanoma specimens that predicted response to anti–programmed cell death-1 (PD-1)–based therapy, including CD163+PD-L1– myeloid cells and CD8+FoxP3+PD-1low/mid T cells. These features were combined to stratify long-term survival after anti–PD-1 blockade. This signature was validated in an independent cohort of patients with melanoma from a different institution.
DOI: 10.1126/science.aba2609
Source: https://science.sciencemag.org/content/372/6547/eaba2609